Novellus Systems acquired by Lam Research Corporation
Eterna Therapeutics develops off-the-shelf cellular therapies using induced pluripotent stem cell-derived mesenchymal stem cells (iMSCs) that express pro-inflammatory cytokines IL-7 and IL-15 to target solid tumors. This approach addresses the limitations of traditional MSC therapies by providing a consistent and scalable source of cells that enhance T-cell anti-tumor activity while minimizing systemic exposure and toxicity.
- Biotechnology
Funding
Founders
Founder details are not available yet.
Product
Problem
Traditional mesenchymal stem cell (MSC) therapies for solid tumors suffer from inconsistent therapeutic outcomes due to MSC heterogeneity, batch-to-batch variability, limited proliferative capacity, and early senescence. These limitations hinder the development of scalable and reliable off-the-shelf cell therapies.
Solution
Eterna Therapeutics is developing off-the-shelf cellular therapies using induced pluripotent stem cell-derived mesenchymal stem cells (iMSCs) to address the limitations of traditional MSC therapies. Their proprietary mRNA-based platform enhances iPSC generation, enabling a scalable iMSC product that delivers pro-inflammatory cytokines (e.g., IL-7 and IL-15) selectively to tumors. This targeted approach limits systemic exposure and potential toxicity while enhancing T-cell anti-tumor activity. By using iMSCs, Eterna aims to provide a consistent and rejuvenated source for allogeneic therapies.
Target Audience
The primary target audience includes patients with advanced solid tumors and the clinicians treating them.
Features
- iMSCs derived from homogeneous, well-characterized cell lines under controlled conditions
- Proprietary mRNA-based platform enhances iPSC generation
- Designed to deliver IL-7/IL-15 selectively to tumors
- Enhanced T-cell anti-tumor activity
- Scalable, off-the-shelf iMSC product